

AUG 24 2005

K052132  
Page 1 of 2

510(k) Summary

**1. Submitter's Name and Address:**

Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA 92614

**2. Contact:**

Kevin Drisko  
Sr. Regulatory Manager  
Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA 92614  
Phone: 949-250-2416  
FAX: 949-250-3630  
E-Mail: [kevin\\_drisko@edwards.com](mailto:kevin_drisko@edwards.com)

**3. Date Prepared:**

August 4, 2005

**4. Device Trade Name:**

LifeStent Valeo Biliary Stent System

**5. Device Common Name:**

Biliary Stent

**6. Device Classification Name:**

Biliary Catheter (78 FGE), Class II

**7. Predicate Devices:**

LifeStent SDS/XL SDS Biliary Stent Systems (K023308, K033212, K040550, K041032)  
LifeStent Turbo Biliary Stent System (K050627)

## 510(k) Summary (continued)

### 8. Device Description:

The LifeStent Valeo consists of a balloon expandable stent that is provided on an over-the-wire catheter that acts as a delivery system. The stent is a permanently implanted device used to maintain patency of a major bile duct obstructed by tissue of an impinging tumor. The flexible, balloon expandable stent is made by laser cutting an open lattice design into a stainless steel tube. The stent is supplied mounted onto a PTA balloon catheter, inserted percutaneously to the diseased site and expanded by balloon inflation. The subject device is supplied in lengths of 17/18mm, 26mm, 36 mm and 56mm and diameters of 6mm, 7mm, 8mm, 9mm and 10mm.

### 9. Intended Use:

The LifeStent Biliary Stent Systems are indicated for use in the palliation of malignant strictures (neoplasms) in the biliary tree.

### 10. Technological Characteristics:

Comparisons of the subject and predicate devices show that the technical characteristics such as materials, performance properties, biocompatibility, method of sterilization, and packaging are identical or substantially equivalent.

### 11. Performance Data:

Edwards Lifesciences completed bench testing such as deployment testing, dimensional testing, balloon performance testing, stent deformation testing as well as tensile strength testing on applicable joints of the delivery system. The results indicate that the system performed in a manner substantially equivalent to the predicate devices cited in item 7 above.

### 12. Conclusion:

Since the LifeStent Valeo has the same intended use, similar materials, similar performance properties, packaging and sterilization methods, it may be considered substantially equivalent to the predicate device cited in item 7 above.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**AUG 24 2005**

Mr. Kevin Drisko  
Senior Manager, Regulatory Affairs  
Edwards Lifesciences LLC  
One Edwards Way  
IRVINE CA 92614

Re: K052132  
Trade/Device Name: Edwards Lifesciences LifeStent Valeo Biliary Stent System  
Regulation Number: 21 CFR §876.5010  
Regulation Name: Biliary catheter and accessories  
Regulatory Class: II  
Product Code: FGE  
Dated: August 4, 2005  
Received: August 11, 2005

Dear Mr. Drisko:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

Page 2 – Mr. Kevin Drisko

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4616. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Donna-Bea Tillman, Ph.D.

Director

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number: K052132

Device Name: Edwards Lifesciences LifeStent Valeo Biliary Stent System

FDA's Statement of the Indications For Use for device:

The Edwards Lifesciences LifeStent Valeo Biliary Stent Systems are indicated for use in the palliation of malignant strictures (neoplasms) in the biliary tree.

Prescription Use    
 (Per 21 CFR 801.109)

OR

Over-the-Counter Use

Nancy C Brogdon  
(Division Sign-Off)  
Division of Reproductive, Abdominal, and  
Radiological Devices  
510(k) Number K052132